Sarepta Therapeutics (SRPT) Total Non-Current Liabilities (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Total Non-Current Liabilities of $1.7 billion for Q1 2026, down 26.51% year-over-year from $2.3 billion in Q1 2025, and down 24.25% quarter-over-quarter from $2.2 billion in Q4 2025.
Sarepta Therapeutics (SRPT) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $1.7 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 26.51% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $1.7 billion (down 26.51% YoY), while the FY2025 annual figure was $2.2 billion, down 7.56% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $1.7 billion, down from $2.2 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $2.7 billion in Q4 2022, with the low at $1.7 billion in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $2.3 billion (2024), against an average of $2.3 billion.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities increased 25.1% in 2022, then decreased 26.51% in 2026.
- Sarepta Therapeutics' Total Non-Current Liabilities stood at $2.7 billion in 2022, then dropped by 12.54% to $2.4 billion in 2023, then rose by 0.88% to $2.4 billion in 2024, then declined by 7.56% to $2.2 billion in 2025, then declined by 24.25% to $1.7 billion in 2026.
- Business Quant data shows SRPT's Total Non-Current Liabilities at $1.7 billion in Q1 2026, $2.2 billion in Q4 2025, and $2.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 1.66 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Bn |
| Mar 31, 2026 | 1.67 Bn |
| Dec 31, 2025 | 2.21 Bn |
| Sep 30, 2025 | 2.14 Bn |
| Jun 30, 2025 | 2.28 Bn |
| Mar 31, 2025 | 2.28 Bn |
| Dec 31, 2024 | 2.39 Bn |
| Sep 30, 2024 | 2.33 Bn |
| Jun 30, 2024 | 2.30 Bn |
| Mar 31, 2024 | 2.21 Bn |
| Dec 31, 2023 | 2.37 Bn |
| Sep 30, 2023 | 2.31 Bn |
| Jun 30, 2023 | 2.35 Bn |
| Mar 31, 2023 | 2.31 Bn |
| Dec 31, 2022 | 2.71 Bn |
| Sep 30, 2022 | 2.69 Bn |
| Jun 30, 2022 | 2.26 Bn |
| Mar 31, 2022 | 2.19 Bn |
| Dec 31, 2021 | 2.18 Bn |
| Sep 30, 2021 | 2.15 Bn |